Strategic Focus Cardiol Therapeutics is a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, with lead candidate CardiolRx and a growing pipeline including CRD-38 for heart failure, presenting multiple collaboration and licensing opportunities with pharma, CROs, and specialty distributors.

FDA Programs With FDA Orphan Drug Designation for recurrent pericarditis and IND-enabled programs for acute myocarditis, there are potential co-development, grant, and milestone- driven funding conversations with regulators, payers, and potential strategic partners seeking accelerated access.

Clinical Milestones Key upcoming milestones from MAVERIC and ARCHER trials create near-term engagement windows for investigators, contract research organizations, and investor relations outreach to support trial recruitment, site partnerships, and data-driven discussions with health systems.

Market Opportunity Heart failure and inflammatory heart diseases represent large, cost-bearing markets; CRD-38 and CardiolRx offer entry points for hospital systems, cardiology clinics, and specialty pharmacies seeking innovative therapies to address high hospitalization rates and $30B+ U.S. costs associated with heart failure.

Strategic Partnerships The company’s global listings (NASDAQ and TSX), active investor engagement, and ongoing conferences provide fertile ground for partnering with biotech developers, contract manufacturers, and distribution networks to accelerate clinical-to-commercial transitions and broaden geographic reach.